Background and Objective: Coronary restenosis after drug-eluting stent (DES) implantation occurs more fre-quently in diabetic patients than in nondiabetic patients. We compared the parameters influencing the like-Subjects and Methods: Pat-ients who underwent DES implantation (619 patients with 917 lesions, 21 diabetics and 408 nondiabetics), folowed by 8 months coronary angiogram, were retrospectively identified using the percutaneous coronary intervention database and included in the present study [AH1]. Predictors of restenosis were identified by multivariate logistic regression analyses. Results: The baseline characteristics of the patients, such as sex, body mas index, hypertension, hyperlipidemia, and smoking status, were similar betwen the diabetic and nondiabetic patients. Restenosis (>50% of the diameter stenosis) occured in 32 of 408 (7.8%) nondiabetic patients and in 32 (15.2%) of 21 diabetic patients (p<0.001). The use of a paclitaxel-eluting stent (PES), a higher level of C-reactive protein (CRP), longer stent length, smaler reference diameter (RD) before DES implantation, smaller RD and minimal lumen diameter after DES implantation were comon predictors of restenosis in both the diabetic and nondiabetic patients after multivariate analyses. Curent smoking status [odds ratio (OR)= 3.213, 95% confidence interval (CI) = 0.004] and right coronary lesions (OR= 2.444, 95% CI 1.048 to 5.703, p=0.039) were predictors of restenosis in the diabetic patients, while higher body mas index (OR= 1.322, 95% CI 1.054 to 1.659, p=0.016) and A-type lesions (OR= 0.108, 95% CI 0.022 to 0.530, p= 0.06 ) were predictors of rest-enosis in the nondiabetic patients. Conclusion: The use of PESs and higher levels of CRP were associated with restenosis regardles of the presence of diabetes. Moreover, small baseline and post-PCI reference diameter and patients, even in the era of DES implantation